Back to top

Analyst Blog

Zacks Equity Research

Mylan, Pfizer Settle Patent Dispute

PFE MYL

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Mylan Inc. (MYL - Analyst Report) recently announced that it has entered into a settlement agreement with Pfizer Inc. (PFE - Analyst Report), Pharmacia & Upjohn Company LLC and Pfizer Health AB. The patent litigation was related to Mylan’s generic version of Pfizer’s Detrol LA (tolterodine tartrate ER, 2 mg and 4 mg) for overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Under the terms of the settlement agreement, subject to regulatory approval, Mylan can launch its generic version of Pfizer’s Detrol LA between January 1, 2014 and March 1, 2014. Other terms of the deal were not disclosed.

According to IMS Health, Detrol LA, 2 mg and 4 mg, generated US revenues of approximately $599 million for the 12 months ending June 30, 2012.

This news comes on the heels of the Mylan-Pfizer collaboration to develop, manufacture, distribute and commercialize generic drugs in Japan, announced last month.

Our Recommendation

We are encouraged by Mylan’s geographic reach and product depth, along with a robust generic product pipeline. However, we remain concerned about the company’s lackluster performance in Europe, Middle East and Africa (EMEA) region. Additionally, with most large branded drugs due to lose patent exclusivity within the 2017-2018 period, we have little visibility on the growth prospects of generic companies like Mylan beyond that timeframe.

Thus, we prefer to remain on the sidelines and have a Neutral recommendation on Mylan. The stock carries a Zacks #2 Rank (Buy rating) in the short term. We currently have a Neutral recommendation on Pfizer, which carries a Zacks #3 Rank (short-term ‘Hold’ rating).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%